Gan & Lee Pharma Accelerates Revenue Growth While Investing 33% in R&D for Breakthrough Drugs
Gan & Lee Pharma pushes 33% R&D spend to fuel 40 bn RMB revenue, aiming breakthroughs in diabetes and other high‑growth therapies. Learn how innovation fuels its market‑lead success.
3 minutes to read